The Bispecific Combination Wave Is Here: What the Englumafusp-Glofitamab Trial Signals for Hematology Trial Design

Call it the Bispecific Stacking Problem. Three converging signals from the past 18 months, culminating in the Phase 1 trial of englumafusp alfa plus glofitamab published in Nature Medicine, point to a pattern most clinical operations teams have not operationally prepared for: the move from single-agent bispecifics into rational combination regimens that layer co-stimulatory mechanisms on top of T-cell engagers. This is not incremental. It fundamentally changes how you design a dose-escalation study, how you recruit patients who have already been exposed to prior bispecific lines, and how you monitor for toxicities that no existing grading schema was built to capture together.

The industry celebrated glofitamab‘s approval. Now it needs to think harder about what comes next.

Signal One: Co-Stimulation Enters the Bispecific Equation

Open the Phase 1 data from trial BP41072 and the mechanistic rationale alone should stop a clinical operations director mid-slide. Englumafusp alfa is a CD19-4-1BBL co-stimulatory antibody-like fusion protein, designed to do something that CD20-targeting bispecifics like glofitamab cannot do on their own: simultaneously target CD19 on B cells while delivering a 4-1BB co-stimulatory signal that augments T-cell activation and limits T-cell exhaustion. That last phrase is the critical one. T-cell exhaustion has been the silent ceiling on bispecific monotherapy durability. You recruit T cells through the CD20xCD3 mechanism, you get responses, and then the T cells wear out. The combination is explicitly designed to interrupt that cycle.

According to data reported by Cancer Network, the BP41072 trial showed encouraging activity with a safety profile consistent with glofitamab monotherapy, suggesting the combination does not catastrophically amplify the cytokine release syndrome burden that has defined single-agent T-cell engager trials. That is a meaningful early signal. But it is also exactly the kind of signal that creates false operational confidence, because “consistent with monotherapy” in Phase 1 dose escalation tells you almost nothing about what happens when you move into Phase 2 expansion cohorts with higher-exposure patients and longer treatment durations.

The mechanistic question this trial raises for trial designers is uncomfortable: if 4-1BB co-stimulation is extending T-cell functionality, you have created a moving immunological target. Your toxicity monitoring windows, your cytokine panels, your grading criteria for immune effector cell-associated neurotoxicity syndrome, all of which were calibrated for the glofitamab monotherapy experience that supported its FDA accelerated approval in June 2023, may be measuring the wrong things on the wrong timeline.

Signal Two: The Prior Bispecific Exposure Problem

Here is the counterintuitive reality that sponsors designing combination bispecific trials in 2026 need to confront directly: glofitamab’s own approval created the patient population problem for every trial that follows it.

When glofitamab-gxbm (Columvi) received accelerated approval for relapsed or refractory DLBCL after two or more prior lines of systemic therapy, it entered the treatment algorithm for exactly the population that downstream combination trials will need to recruit. Mosunetuzumab (Lunsumio), approved for follicular lymphoma, occupied another segment of that heavily pretreated space. As Blood Cancer United documented, mosunetuzumab was the first bispecific approved in follicular lymphoma, and both approvals happened within a compressed window. The result is that patients entering Phase 1 or Phase 2 combination trials in B-cell NHL today frequently carry prior CD20 bispecific exposure, prior CAR-T exposure, or both. Their T-cell compartments are not naive. Their CD20 antigen expression may be altered or lost.

Research published in Blood demonstrates that CD20-bispecific antibodies improve CD19-CAR T-cell response through two mechanisms: recruiting and activating endogenous T cells, and supporting CAR T-cell proliferation. But the inverse question, what prior CD20 bispecific exposure does to a patient’s eligibility and response in a subsequent T-cell co-stimulatory combination, remains operationally unanswered in most protocol eligibility criteria. Sponsors are writing inclusion and exclusion criteria using assumptions built on treatment-naive bispecific populations, then enrolling patients whose immune profiles look nothing like those assumptions.

This creates a site-level chaos that statisticians rarely model for: patients who technically meet eligibility criteria but whose underlying biology invalidates the dose-escalation assumptions the protocol was built on.

Signal Three: Adaptive Design Is No Longer Optional Here

The BP41072 trial’s safety findings, while encouraging, also reveal the structural limitation of conventional 3+3 dose-escalation designs when the mechanism involves both a direct cytotoxic engagement and a co-stimulatory amplifier working in sequence. A 3+3 design observes a small number of patients per dose level and makes binary go/no-go decisions based on dose-limiting toxicities defined in a DLT window that was set before you understood how the combination’s immunological activity unfolds over time. When 4-1BB co-stimulation extends T-cell persistence and activity beyond the standard 28-day DLT observation window, the 3+3 architecture is structurally blind to delayed immune-mediated toxicities.

Bayesian optimal interval designs, model-assisted approaches like BOIN, and adaptive dose-finding frameworks are not theoretical improvements here. For combination bispecific trials specifically, they are the appropriate methodology. The FDA has issued guidance on model-informed drug development and adaptive designs, and the agency’s 2019 guidance on adaptive designs explicitly supports the use of Bayesian frameworks in early-phase oncology when the dose-toxicity relationship is uncertain. When you are layering a co-stimulatory fusion protein onto an already complex bispecific mechanism, uncertainty about the dose-toxicity relationship is not a possibility. It is a certainty.

Sponsors who submit conventional Phase 1 combination protocols without pre-specified adaptive decision rules for DLT window extension are not being conservative. They are producing data that will not answer the questions the Phase 2 team actually needs answered.

What This Means for Sponsors, Sites, and Vendors

For sponsors, the BP41072 data should accelerate a protocol architecture review for any combination bispecific program currently in IND-enabling or pre-IND stages. The specific question is not whether the combination works, it is whether the dose-escalation methodology will generate a pharmacologically interpretable recommended Phase 2 dose in a population with prior bispecific exposure. Glofitamab monotherapy in its pivotal study enrolled patients across relapsed/refractory LBCL subtypes and generated an independently reviewed complete response rate that supported accelerated approval, but that population preceded widespread bispecific availability in clinical practice. The 2026 relapsed/refractory patient is a different patient, and the Phase 1 infrastructure needs to account for that.

For sites, combination bispecific trials require a monitoring infrastructure that most academic medical centers built for single-agent CAR-T or single-agent bispecific programs. Cytokine release syndrome grading, ICANS assessment, and the 24-hour response protocols that those programs require exist in most major centers. What does not routinely exist is the pharmacodynamic monitoring capacity to track 4-1BB-mediated T-cell co-stimulatory activity over extended timeframes, which is precisely the mechanistic variable that makes a combination like englumafusp alfa plus glofitamab scientifically interesting and operationally demanding. Sponsors who assume existing site infrastructure maps to combination bispecific requirements will discover the gap in the first interim safety review.

The counterintuitive implication for eClinical technology vendors is worth stating plainly. The reflex assumption is that the complexity of combination bispecific trials drives demand for more sophisticated EDC configurations and eCOA instruments. That is true but secondary. The primary technology gap is in risk-based monitoring platforms that can integrate immunological biomarker data, real-time safety signals, and adaptive decision triggers into a single operational view. The current generation of RBM platforms was built to detect site-level data quality deviations, not to flag when a patient’s cytokine trajectory at day 35 suggests a DLT window extension is warranted. That capability does not yet exist in commercial platforms at the scale combination bispecific trials will require.

The FDA’s accelerated approval of glofitamab in June 2023 was, in retrospect, the starting gun for a generation of combination programs that will stress-test every assumption built into standard Phase 1 oncology trial infrastructure. The englumafusp alfa data published in Nature Medicine is the first clear signal of where that stress is going to land: in the DLT observation window, in the eligibility criteria for prior bispecific exposure, and in the monitoring platforms that were never designed for a mechanism that keeps T cells active long after the protocol says the observation period is over. The sponsors who adapt their Phase 1 architecture now will reach a readable recommended Phase 2 dose. The ones who do not will spend 18 months explaining to their Phase 2 team why the dose they selected does not behave the way the Phase 1 data said it would.

References

1. Nature Medicine — “Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial”
2. FDA — “FDA Grants Accelerated Approval to Glofitamab-gxbm for Selected Relapsed or Refractory Large B-Cell Lymphoma” (June 15, 2023)
3. Cancer Network — “Englumafusp Alfa Combo Shows Encouraging Activity in B-Cell Lymphoma”
4. Blood Cancer United — “FDA Approves First-in-Class Bispecific Antibody Treatment for Follicular Lymphoma”
5. Blood (ASH Publications) — “CD20-bispecific antibodies improve response to CD19-CAR T cells”